サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1133478

静脈疾患治療の世界市場-2022-2029

Global Venous Diseases Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
静脈疾患治療の世界市場-2022-2029
出版日: 2022年10月11日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

静脈疾患治療市場の成長は、静脈疾患の有病率の上昇、レーザーアブレーション手順の需要増加、静脈疾患治療の採用率の上昇、老年人口の増加、研究活動によってもたらされるものです。

静脈疾患の有病率上昇は、市場成長を促進すると予想されます。

血栓深部静脈血栓症や慢性静脈不全など、さまざまな静脈疾患の有病率の上昇は、予測期間中の市場を押し上げると予想されます。2021年にマカ、ジェッダ、ダンマームでBawakidらによって報告された研究では、男女ともに45.6%の慢性静脈不全の全体的な有病率に言及されています。また、2021年にサウジアラビア地域のカシム地域のプライマリーヘルスケアセンターで行われた有病率調査では、男女の静脈瘤の有病率は61.1％であったことが明らかになりました。ドップラー超音波検査と結合した新しいアンケートベースの研究は、韓国で示された女性の看護師の静脈瘤の少ない有病率16.18パーセントを報告しました。これは、ライフスタイルの変化や医療へのアクセスの進歩の急速な変化に割り当てることができます。静脈瘤を持つ人々は、最も一般的なCEAPクラスは、この研究の女性の間で毛細血管拡張症や網状静脈として提示疾患の軽症型を示し、C1でした。また、年齢は私たちの体の静脈瘤の開発と進行を上昇させる主要な貢献の危険因子です。

年齢の増加は、さらに皮膚の栄養変化、血管内圧の成長、および表在静脈系の不能の重要な要因です。さらに、欧州のフランスのさまざまな場所で行われた大規模な研究では、妊婦の72.7％が静脈瘤に悩まされていることを報告しました。また、高いボディマス指数（BMI）は、静脈瘤のより高度なステージに関連付けられています。さらに、ライフスタイルの速い変化とソーシャルメディアを通じて具体的に医療への容易なアクセスを通じて静脈瘤とその危険因子についての意識の高まりは、静脈疾患治療市場を駆動します。

静脈疾患治療の高コストは、市場の成長を妨げるだろう

しかし、そのような静脈焼灼時の感染症、痛みや炎症、あざ、血栓、および、腫れなどの静脈疾患治療に関連する副作用。また、脚や足の痛みや重さ、特に長時間立ったり歩いたりした後や、脚の灼熱感やけいれんは、市場の成長を阻害する要因となります。

COVID-19の影響分析

COVID-19の登場は、世界の静脈疾患治療市場に大きな影響を与えました。2020年7月にセージジャーナルに掲載された記事のように、COVID-19の大流行は、コロナウイルスに感染した患者の重要な物資、労働力、緊急および集中治療室（ICU）施設などの医療資源の逸脱をもたらしました。米国をはじめとする多くの国では、外科手術が延期またはキャンセルされ、手術室のリソースはパンデミックの管理に集中されました。直接の個人的接触が制限され、社会的距離を置くことで、治療へのアクセスが制限されました。静脈やリンパの障害、血管の異常がある患者は、パンデミックの中で専門的な治療を受けることが困難となっています。さらに、動脈および静脈血栓塞栓症（VTE）と広範な凝固異常を伴うCOVID-19は、罹患者の診断がさらに困難であるという証拠が増えつつあります。状況はCOVID-19から回復しているように静脈の治療でより多くの患者が簡単に市場を駆動する適切な治療にアクセスすることができます。

世界の静脈疾患治療市場レポートは、約50以上の市場データ表、50以上の図、および200ページ（概算）の範囲でのアクセスを提供するであろう。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 治療タイプ別：市場内訳
  • 疾患タイプ別：市場内訳
  • 製品タイプ別：市場内訳
  • エンドユーザー別：市場内訳
  • 流通チャネル別：市場内訳
  • 地域別：市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 静脈疾患の発生率の上昇
      • 研究開発の増加
    • 抑制要因
    • 治療薬に関連する副作用
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • 価格設定分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 治療タイプ別

  • 外科手術
  • 硬化療法
  • 血管形成術またはステント留置術
  • 静脈結紮術およびストリッピング
  • 大静脈フィルター
  • 外来静脈瘤切除術
  • ラジオ波焼灼療法
  • レーザー治療
  • その他の治療法

第8章 疾患タイプ別

  • 深部静脈血栓性静脈炎
  • 下肢静脈瘤・クモ状静脈
  • 表在性血栓性静脈炎
  • 慢性静脈不全
  • 静脈潰瘍
  • その他

第9章 製品タイプ別

  • アブレーションデバイス
  • 静脈ステント
  • 静脈クロージャー
  • 硬化療法用注射剤
  • その他

第10章 エンドユーザー別

  • 病院
  • クリニック
  • 外来センター
  • その他

第11章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第13章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第14章 企業プロファイル

  • Biolitec AG Untere Viaduktgasse
    • 企業概要
    • 治療タイプのポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Teleflex Incorporated
  • BD
  • B. Braun Melsungen Ag
  • Alma Lasers
  • Becton Dickinson and Company
  • Koninklijke Philips N.V.

第15章 静脈疾患治療の世界市場-DataM

目次
Product Code: DMPH5853

Market Overview

Venous Diseases Treatment Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

The venous disease includes blood clots in the legs, arms, brains, lungs, or internal organs (kidney, spleen, liver), deep vein thrombosis, chronic venous insufficiency, varicose and spider veins, and ulcers in the vein. The treatment for this disease includes drug therapy, endovenous laser ablation or radiofrequency ablation (RFA), sclerotherapy, and surgery.

Market Dynamics

The Venous Diseases Treatment market growth is driven by the rise in the prevalence venoous disease, rising demand for laser ablation procedures, rising adoption of venous diseases treatment, increase in the geriatric population, and research activities.

The increasing prevalence of venous diseases is expected to drive the market growth

The rising prevalence of different venous diseases such as blood clots deep vein thrombosis, and chronic venous insufficiency is expected to boost the market over the forecast period. In 2021, a study reported by Bawakid et al. in Makah, Jeddah and Dammam mentioned an overall prevalence of chronic venous insufficiency of 45.6% in both males and females. Also, a prevalence study conducted in 2021, in primary health care centers in Qassim region of Saudi Arabia region revealed that the prevalence of varicose veins among male and female was 61.1%. A new questionnaire-based study coupled with Doppler ultrasonography was showed in Republic of Korea reported less prevalence of varicose veins in female nurses 16.18%. This could be allocated to the rapid of changes in lifestyle and advancement in access to health care. Those people with varicose veins, the most commonly CEAP class was C1 which indicates a mild form of the disease presenting as telangiectasia or reticular veins among females in this study. In addition, age is a major contributing risk factor that rises the development and progression of varicose veins in our body.

Increasing in age is a significant factor in further skin trophic changes, growth in the endovascular pressure, and inability of the superficial venous system. Moreover, a large study done in different locations of France in Europe reported that 72.7% of pregnant women are suffering from varicose veins. Also, higher Body Mass Index (BMI) is associated to more advanced stages of varicose veins. Furthermore, fast changes in lifestyle and increased awareness about varicose veins and its risk factors through easier access to health care specifically through social media drives the venous disease treatment market.

The high cost of Venous Diseases Treatment will hamper the growth of the market

However, side effects associated with veous disease treatment such as infection during venous ablation, soreness and inflammation, bruising, blood clots and, swelling. In addition, pain and heaviness in the legs and feet, especially after long a time standing or walking for long periods of time and ,burning, and cramping in the legs restarestraintsmarket growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global venous diseases treatment market. As per the article published in Sage journals in July 2020, The COVID-19 pandemic has resulted in deviation of healthcare resources such as critical supplies, workforce, emergency and intensive care unit (ICU) facilities of patients infected with coronavirus. Interuuptions in surgical procedures in most countries such as United States had been postponed or cancelled and operating room resources were focused on management of the pandemic. Restrictions to direct personal contact and social distancing have controlled the access to care. Patients with venous and lymphatic disorders or vascular anomalies faced difficulty to get expert care in pandemic. In addition, there is increasing evidence that COVID-19 with both arterial and venous thromboembolic (VTE) disease and extensive coagulopathies is additionally difficult of the diagnosis of the affected patients. As the situation is recovering from COVID-19 more patients with venous treatment can easily access the proper treatment which drives the market.

Segment Analysis

The chronic venous insufficiency segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic venous insufficiency segment is expected to boost the market over the period of the forecast. In 2022, the article published in Dermatol Therpeutics, chronic venous disorder (CVD) is most prevalent vascular disorder affecting up to 45% of the general population, with clinical relevation ranging from teleangiectasias to venous leg ulcers. The prevalence of CVD rises with age and it is more familiar in female than male. However, estimates of CVD prevalence vary widely from study to study 15-80% due to differences in study design and target population, and most of time CVD is underdiagnosed and undertreated, especially at lower severity levels. The pharmacological treatment can give proper symptomatic relief and it is considered as part of conservative treatment. Transcutaneous Lacer treatment is a safe and effective alternative option to sclerotherapy for treatment of C1 stage. Ultrasound-guided foam sclerotherapy (UGFS), high ligation and stripping, endovenous thermal ablation (EVTA) systems and non thermal non tumescent ablation systems are safe and effective first-line options for treatment of saphenous insufficiency.

Furthermore, in january 2022, The European Society for Vascular Surgery (ESVS) has published 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 guidelines. The new guidelines foused on CVD of the lower limbs, related to pathology of the superficial, perforating and deep veins of the lower limb as well as to abdominal and pelvic venous pathology.

Geographical Analysis

North America region holds the largest market share of the global venous diseases treatment market

North America dominates the market for venous diseases treatment and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to technological advancement, presence of key players and easily availability of treatment. The article published in 2020 in J Vasc Surg Venous Lymphat Discord. Chronic venous insufficiency (CVI) resulting from venous reflux or obstruction leads to venous hypertension with edema, varicose veins, consequent pain, hyperpigmentation, and ulceration of the lower extremities. The CVI affects approximately 25 million adults in the United States region, with around 6 million suffering from advanced disease, and the annual cost of venous ulcer treatment and care is anticipated to be nearly $3 billion. Furthermore, for those people who are working for them CVI accounts for a loss of 2 million workdays per year, and almost 12% seek early retirement. Prolonged standing, Female sex, pregnancy, obesity; advanced lifestyle, venous reflux or obstruction, and deep venous thrombosis (DVT) are suspected risk factors for CVI. The increasing number of venous disease patient boosts the venous disease treatment market.

Competitive Landscape

The venous diseases treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Biolitec AG Untere Viaduktgasse, Teleflex Incorporated, B. Braun Melsungen Ag, Alma Lasers, Becton Dickinson and Company, and Koninklijke Philips N.V. among others. The major players are adopting several growth strategies such as treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the venous diseases treatment market globally.

For instance,

  • In February 2022, Becton, Dickison, and Company acquired Venclose Inc., a contributor of solutions for the treatment of chronic venous insufficiency (CVI) a disease that is the result of malfunctioning valves and can lead to varicose veins.

Becton, Dickison and Company

Overview:

The Becton, Dickinson and Company is an American multinational company that manufactures and distributes instrument systems, medical devices, and reagents for treatment of various diseases including venous disease.

Treatment Type Portfolio:

Venclose radiofrequency (RF) Ablation System: This system offers transformative solutions to improve outcomes in patients for chronic disease and able to the transition into novel care settings.

The global venous diseases treatment market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Treatment Type
  • 3.2. Market Snippet By Disease Type
  • 3.3. Market Snippet By Product Type
  • 3.4. Market Snippet By End User
  • 3.5. Market snippet By Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of venous diseases
      • 4.1.1.2. The increasing number of research and development activities
    • 4.1.2. Restraints:
    • 4.1.3. Side effects related to therapeutics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Surgeries*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Sclerotherapy
  • 7.4. Angioplasty or Stenting
  • 7.5. Vein Ligation and stripping
  • 7.6. Vena Cava Filter
  • 7.7. Ambulatory Phlebectomy
  • 7.8. Radiofrequency Ablation Therapy
  • 7.9. Laser Treatment
  • 7.10. Others Therapies

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Deep-vein Thrombophlebitis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Varicose and Spider Veins
  • 8.4. Superficial Thrombophlebitis
  • 8.5. Chronic Venous Insufficiency
  • 8.6. Venous Ulcers
  • 8.7. Others

9. By Product Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.1.2. Market Attractiveness Index, By Product Type
  • 9.2. Ablation Devices*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Venous Stents
  • 9.4. Venous Closure Products
  • 9.5. Sclerotherapy Injection
  • 9.6. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Centers
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Treatment type Benchmarking

14. Company Profiles

  • 14.1. Biolitec AG Untere Viaduktgasse*
    • 14.1.1. Company Overview
    • 14.1.2. Treatment type Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Teleflex Incorporated
  • 14.3. BD
  • 14.4. B. Braun Melsungen Ag
  • 14.5. Alma Lasers
  • 14.6. Becton Dickinson and Company
  • 14.7. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

15. Global Venous Diseases Treatment market- DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us